Abstract
Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy both in Europe and in the United States. Follicular lymphoma (FL), a tumor comprised of mature B cells, represents one fourth of all NHL and, despite good response rates to standard treatments, tends to frequently relapse to such an extent that it is still considered incurable. Among several alternative therapeutic options actively being pursued, immunotherapy by idiotypic vaccination is in the forefront of clinical experimental medicine. The idiotype vaccine consists of the tumor-specific immunoglobulin conjugated with keyhole limpet hemocyanin (KLH) and administered together with an adjuvant. Over the last 20 years, researchers have proven that this vaccine can induce specific immune responses. Too, those patients with such responses experience a disease-free survival longer than normally achievable, although these latter results require further confirmation in large clinical trials. Traditionally, idiotype vaccines have been produced through hybridoma technology. In this chapter this technology is described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kobrin CB, Kwak LW (1997) Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest 15:577–587
Hawkins RE et al (1994) Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83(11):3279–3288
Bendandi M et al (2001) Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann Oncol 12(10):1479–1484
Carroll WL et al (1986) Mouse × human heterohybridomas as fusion partners with human B-cell tumors. J Immunol Methods 89:61–72
Rodríguez-Calvillo M et al (2004) Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol 52:1–7
Grodzki AC, Berenstein E (2010) Antibody purification: ammonium sulfate fractionation or gel filtration. In: Oliver C, Jamur MC (eds) Immunocytochemical methods and protocols, vol 588, Methods in molecular biology. Humana, Totowa, pp 15–26
Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
Gagnon PS (1996) Purification tools for monoclonal antibodies. Validated Biosystems. In: Rathore Gail Sofer AS (ed) Process validation in manufacturing of biopharmaceuticals, 3rd edn. CRC, Tuscon, AZ
Nethery A et al (1990) Single-step purification of immunoglobulin M on C1q-Sepharose. J Immunol Methods 126(1):57–60, Erratum in: J Immunol Methods 130(2), 287
Nevens JR et al (1992) Affinity chromatographic purification of immunoglobulin M antibodies utilizing immobilized mannan binding protein. J Chromatogr 597(1–2):247–256, April 24
Roque-Barreira MC, Campos-Neto A (1985) Jacalin, an IgA-binding lectin. J Immunol 134(3):1740–1743
Aucouturier P et al (1987) Characterization of jacalin, the human IgA and IgD binding lectin from jackfruit. Mol Immunol 24(5):503–511
Kwak LW et al (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Eng J Med 327:1209–1215
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Inoges, S., de Cerio, A.L.D., Villanueva, H., Pastor, F., Bendandi, M. (2014). Idiotype Vaccine Production Using Hybridoma Technology. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_30
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_30
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols